Close menu

October 11th, 2021 | 10:26 CEST

Deutsche Post, Memiontec, Bayer - Here is where the action is

  • Investments
Photo credits:

After heavy losses in recent weeks - the DAX losing more than 1,200 points at its peak and briefly slipping below the 15,000-point mark - the mood is brightening again. The German benchmark index, now made up of 40 members, is back on track for a year-end rally despite concerns about stagflation. The 16,000 peak beckons once again. Individual stocks are likely to outperform in the final weeks of the stock market year based on the recently reported fundamental data.

time to read: 3 minutes | Author: Stefan Feulner
ISIN: DEUTSCHE POST AG NA O.N. | DE0005552004 , Memiontec Holdings Limited | SGXE56008290 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:

    Good conditions

    The signs are favorable for the shareholders of DAX-listed Bayer, who have been suffering for years. As a result of the interminable glyphosate legal disputes that have swallowed up billions, the stock lost more than 60% of its value. It is currently struggling to find a bottom in the zone around EUR 47, close to the 10-year low. Breaking above the EUR 50 mark could breathe new life into the share price. A dynamic move to the EUR 75 area, i.e. a 50% chance, would not be unrealistic in this case.

    The Leverkusen-based Company was able to achieve at least a first partial success in the glyphosate dispute. After losing three lawsuits, Bayer was able to win a case for the first time. A court in Los Angeles ruled that the weed killer glyphosate did not cause a boy's cancer.

    The news that the agrochemicals and pharmaceuticals group was seeking to sell its "Environmental Science Professional" (ESP) division also had a positive effect. As reported by the Bloomberg news agency, a trade sale is likely to bring around EUR 2 billion into the Company's coffers. There are enough interested parties, such as Blackrock and CVC. However, neither Bayer nor various financial investors commented on the news.

    Fantastic development

    The share of Memiontec, the holding Company from Singapore, showed an unparalleled development on the stock exchange floor. The share has gained around 200% in the last 8 weeks alone - we drew your attention to the stock at the time - and is quoted at EUR 0.46 in Frankfurt. The reasons are obvious. Memiontec has been a leader in developing complete water and wastewater management solutions in Singapore, China, and Indonesia for 20 years. It can cover the entire value chain through its 4-pillar model, leading to high scaling effects in the long term.

    In addition to providing total solutions, including maintenance contracts and selling modular and customized systems and equipment, the build-own-operate-transfer (BOOT) and transfer-own-operate-transfer (TOOT) segments are the cash cows. Through long-term partnerships with public and private partners, investments are made here in the maintenance of water treatment infrastructures. By selling purified water, Memiontec benefits here in two ways. In addition to revenue from operations, maintenance and services, the Singapore company generates revenue by selling purified water. As the concession contracts have an average term of 25 years, recurring income is thus secured in the long term.

    Most recently, Memiontec won two tenders worth a total of EUR 8.09 million from Singapore's Public Utilities Board. By the end of July, the order backlog had already reached the record level of EUR 58.38 million. In addition to expanding its joint ventures, Memiontec also plans to grow further through mergers and acquisitions. The topic of water and water scarcity is expected to become more mainstream in the coming years. Memiontec is playing in the premier league in this respect.

    Outstanding business year

    Deutsche Post, in particular the DHL segment, is, without doubt, one of the winners of the Corona pandemic and the resulting online boom. Profit forecasts are being raised for the fourth time this year. On Nov. 4, when third-quarter figures are released, management plans to announce new 2021 operating profit figures "against the backdrop of excellent business development." So far, the benchmark is EUR 7 billion.

    "Global trade has accelerated significantly compared to the previous year," explained Post CEO Frank Appel. In addition, e-commerce shipment volumes remain high. "That is why we are optimistic about the upcoming Christmas business." The Company is preparing for possible record volumes in the coming weeks and has built up additional capacity.

    Despite the extremely positive reports, the share is currently in correction mode after a high of EUR 61.29 in mid-September. There is still a gap to be closed at EUR 52.30. At this level, there is also stronger support. In the long term, this could be a good entry opportunity.

    Both Bayer and Deutsche Post offer good long-term entry opportunities at current levels. Although Memiontec has run strongly in recent weeks, the current high level of incoming orders shows a continued positive outlook for the future. The share has enormous long-term potential due to the global water shortage but may be prone to higher volatility in the short term.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.

    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author

    Related comments:

    Commented by André Will-Laudien on January 31st, 2023 | 14:50 CET

    E-mobility 2023: The Tesla hunters are coming! BYD, Lucid Motors, Tocvan Ventures. Will the Varta share now also fly?

    • Mining
    • Gold
    • Electromobility
    • Investments

    It Is hard to believe! The Tesla share is once again making a name for itself. Analysts went into the presentation of the annual figures with cautious expectations because there were many negative rumors surrounding Elon Musk's electronics company: Fewer sales? Cars on stockpile? Again, it came as no one had expected it. Elon Musk delivered and simultaneously mocked all the shorties who wanted to push his stock below USD 100 at the turn of the year. This gambit went badly wrong because Tesla was able to deliver even better figures than expected, and there was no stopping the share. With plus 70% in only 4 weeks, the Tesla share belongs to the shooting stars since the turn of the year - the short sellers must have lost their desire completely. But the variety of interesting shares is significant. Where are the opportunities for e-investors lurking?


    Commented by Nico Popp on January 31st, 2023 | 14:33 CET

    This new project changes everything: Deutsche Bank, Aspermont, Alibaba

    • Digitization
    • Innovations
    • Technology
    • Investments

    When processes go digital, great opportunities arise: automation and scaling can ensure growth and turn established business models into high-flyers. But which companies should investors actively support in their transformation? Where is there real potential for investors, and where are companies just spreading buzzwords? We highlight three stocks for you.


    Commented by André Will-Laudien on January 30th, 2023 | 09:13 CET

    Mega biotech rally 2023! Defence Therapeutics, Bayer, BioNTech, Morphosys - Where to put the money?

    • Biotechnology
    • Cancer
    • Covid19
    • Investments

    Who would have thought it? Since the beginning of the year, the stock markets have been jubilant despite difficult predictions about the economic trend in 2023. High inflation and rising interest rates are not a good breeding ground for the popular biotech stocks because they have to constantly refinance their research expenses. As the risk fee is readjusted as costs rise, investors demand higher premiums for providing money. However, some biotech stocks have taken off since the beginning of the year despite adverse conditions. What is their secret?